Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares